Drug
Maraviroc clinical trials
Also written Selzentry and Celsentri.
- studies test it
- 119
- open now
- 8
- in phase 3
- 21
- first study started
- 2002
Keep track of what changes. Save the Maraviroc studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
118 studies that test it; most in 2009 (17)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 4 |
| 2007 | 6 |
| 2008 | 10 |
| 2009 | 17 |
| 2010 | 11 |
| 2011 | 13 |
| 2012 | 12 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 32
- Phase 2
- 38
- Phase 3
- 21
- Phase 4
- 31
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 90
ViiV Healthcare (23) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · University of California, San Francisco (4) · St Stephens Aids Trust (4) · University of Maryland, Baltimore (3) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (3) · University of North Carolina, Chapel Hill (3) · Imperial College London (3)
Often tested with
Tested in the same studies.
Tenofovir (8) · Raltegravir (8) · Ritonavir (8) · Emtricitabine (6) · Darunavir (6) · Dolutegravir (4) · Fosamprenavir (3) · Etravirine (2)
Studies
Open first, then newest update. How each study uses Maraviroc is read from its arms, and is right about nine times in ten.
Testing it · 119
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...RecruitingPhase 1/2National Cancer Institute (NCI)NCT05470491Written as Maraviroc
- Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsRecruitingPhase 2Federal University of São PauloNCT06805656Written as Maraviroc
- Anti-inflammation Treatment for Idiopathic Inflammatory MyopathiesNot yet recruitingPhase 4Chinese University of Hong KongNCT07668505Written as maraviroc (Selzentry, Celsentri)
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVIDNot yet recruitingPhase 2/3HealthBio, Inc.NCT06974084Written as Maraviroc (MVC)
- Antiviral Clinical Trial for Long Covid-19RecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06511063Written as Selzentry
- This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft DysfunctionRecruitingPhase 2University of California, San FranciscoNCT06853223Written as Maraviroc
- Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After StrokeRecruitingPhase 2Emmanuel CarreraNCT07080567Written as Maraviroc
- The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After StrokeRecruitingPhase 2University of CalgaryNCT04789616Written as Maraviroc
- Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune RestorationCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00944541Written as maraviroc
- Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesTerminatedNot applicableKevin F. GibsonNCT02134717Written as all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as Maraviroc
- Maraviroc Efficacy for Hepatitis CCompletedPhase 4University of Maryland, BaltimoreNCT02881762Written as Maraviroc
- Maraviroc in Patients With Moderate and Severe COVID-19CompletedPhase 1Rhode Island HospitalNCT04435522Written as Maraviroc
- Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedPhase 1University Hospital HeidelbergNCT04721301Written as Nivolumab plus Ipilimumab plus Maraviroc
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 RatioCompletedPhase 3Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNCT03178084Written as Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID
- Impact of CCR5 Blockade in HIV+ Kidney Transplant RecipientsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02741323Written as Maraviroc
- Safety of Maraviroc for Post-stroke DepressionCompletedPhase 2Tel-Aviv Sourasky Medical CenterNCT05932550Written as Maraviroc 300 mg
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedPhase 1/2SEARCH Research FoundationNCT02475915Written as Maraviroc
- R5 Integrase Study in HIV-1 Naive PatientsCompletedNot applicableUniversity of Maryland, BaltimoreNCT01204905Written as Raltegravir and Maraviroc in combination
- Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCCompletedPhase 1University Hospital HeidelbergNCT03274804Written as Maraviroc
See all 119 studies that test Maraviroc →
Given in every arm · 3 — Maraviroc is usual care beside what is tested
- Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral ReservoirCompletedPhase 2Robert L. MurphyNCT00976404Written as ART intensification (maraviroc)
- Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving MaravirocCompletedPhase 4ViiV HealthcareNCT00853840Written as Maraviroc
- Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal FunctionCompletedPhase 4ViiV HealthcareNCT00717067Written as Maraviroc
As the comparator · 1 — what is tested is compared with Maraviroc
Codes
What other systems call Maraviroc · ClinicalTrials.gg INT006766
- MeSH (NLM) D000077592MaravirocConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) MD6P741W8AMARAVIROCConfirmed FDA, NLM, Wikidata
- RxNorm 620216Confirmed FDA, Wikidata
- Wikidata Q421369maravirocConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73144MaravirocOne source FDA
- DrugBank DB04835One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077592 | Maraviroc | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | MD6P741W8A | MARAVIROC | Confirmed FDA, NLM, Wikidata |
| RxNorm | 620216 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421369 | maraviroc | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73144 | Maraviroc | One source FDA |
| DrugBank | DB04835 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.